Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
antibody drug conjugate
sacituzumab govitecan
trophoblast cell surface antigen 2
urothelial carcinoma
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
23
06
2023
accepted:
15
09
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG) targeting trophoblast cell surface antigen 2 (TROP-2), the protein product of the TACSTD2 gene, have been approved. The expression of TROP-2 was investigated within UC and other types of carcinomas, and within the tissue of different healthy organs to understand treatment responses and toxicities. The expression of TROP-2 in the tissues of 42 patients with UC, 13 patients with other types of cancer and in the normal tissues of 11 patients was retrospectively analyzed. Immunohistochemical staining of the TROP-2 protein was performed on a BenchMark ULTRA IHC/ISH System (Roche Tissue Diagnostics; Roche Diagnostics, Ltd.) according to accredited staining protocols in a routine immunohistochemistry accredited and certified facility of the laboratory of immunohistochemistry at the Institute of Pathology (Gerhard-Domagk Institute)- University Hospital Muenster (UKM)-Muenster-Germany]. Different expression levels of TROP-2 were observed, and the highest expression rate of TROP-2 was observed in UC, independent of the tumor stage. However, normal urothelial cells had similar expression levels. Except for ductal carcinoma
Identifiants
pubmed: 38020299
doi: 10.3892/ol.2023.14114
pii: OL-26-6-14114
pmc: PMC10644361
doi:
Types de publication
Journal Article
Langues
eng
Pagination
527Informations de copyright
Copyright: © Abbas et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Histochem Cytochem. 2011 Jul;59(7):701-10
pubmed: 21551320
Oncotarget. 2017 Apr 25;8(35):58642-58653
pubmed: 28938585
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Adv Urol. 2013;2013:317190
pubmed: 24382958
touchREV Endocrinol. 2021 Apr;17(1):21-32
pubmed: 35118443
Genes Dev. 2012 Oct 15;26(20):2271-85
pubmed: 23070813
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
BMC Cancer. 2017 Jul 14;17(1):486
pubmed: 28709407
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34768978
Oncotarget. 2018 Jun 22;9(48):28989-29006
pubmed: 29989029
PLoS One. 2013 Sep 27;8(9):e75864
pubmed: 24086649
Med Sci (Basel). 2020 Mar 13;8(1):
pubmed: 32183076
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Pathobiology. 2022;89(4):245-258
pubmed: 35477165
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Int J Oncol. 2018 Aug;53(2):515-526
pubmed: 29901071
Curr Oncol. 2022 May 30;29(6):3911-3921
pubmed: 35735421
Cancer. 2015 Aug 1;121(15):2586-93
pubmed: 25872978
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Int J Mol Sci. 2020 Oct 01;21(19):
pubmed: 33019653
Onco Targets Ther. 2019 Mar 01;12:1781-1790
pubmed: 30881031
Oncotarget. 2016 Feb 2;7(5):6136-45
pubmed: 26716416
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Int J Cancer. 1998 Jan 19;75(2):324-30
pubmed: 9462726
EJC Suppl. 2016 Mar;14(1):1-20
pubmed: 27358584